Chulani Karunatilake
Chief Tech/Sci/R&D Officer at WEREWOLF THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Profile
Chulani Karunatilake is currently the Chief Technology Officer at Werewolf Therapeutics, Inc. He previously worked as Vice President at Nektar Therapeutics and Senior Vice President-Technical Operations at Maverick Therapeutics, Inc. He holds a doctorate degree from the University of Illinois and an undergraduate degree from the University of Colombo.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-01 | 0 ( -.--% ) | - $ | 2024-04-29 |
Chulani Karunatilake active positions
| Companies | Position | Start |
|---|---|---|
| WEREWOLF THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-06-14 |
Former positions of Chulani Karunatilake
| Companies | Position | End |
|---|---|---|
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | - |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Corporate Officer/Principal | - |
Training of Chulani Karunatilake
| University of Illinois | Doctorate Degree |
| University of Colombo | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| WEREWOLF THERAPEUTICS, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| Private companies | 1 |
|---|---|
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Health Technology |
- Stock Market
- Insiders
- Chulani Karunatilake